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A recent article from the group in Berlin [1] reports on a 
retrospective review of observational data comparing 
their experience using tranexamic acid as an enforced 
alternative to aprotinin. Th   eir data suggest an increase in 
morbidity and mortality in the tranexamic acid treated 
patients. Is this a cause for concern and what does it 
mean for the future?
Th  e voluntary withdrawal of aprotinin in certain 
markets has had two major eﬀ  ects. Th  e  ﬁ  rst was to cause 
all of the safety and eﬃ     cacy data for aprotinin to be 
independently examined by regulatory authorities in 
both North America and Europe. Th   is process is coming 
to its conclusion and it is anticipated that, based on a 
positive beneﬁ   t-risk ratio, the Canadian authority will 
renew the marketing license for aprotinin before the end 
of this year. Th   e European agency is also starting a review 
[2] but it is not anticipated this process will be completed 
until 2011.
Th  e second eﬀ  ect of the withdrawal of aprotinin was 
that clinicians had to ﬁ  nd an alternative blood-sparing 
agent for use during major cardiac surgery. Th   e two alter-
na  tives are the lysine analogues epsilon aminocaproic 
acid and tranexamic acid. Epsilon aminocaproic acid has 
no approval in Europe or Canada for human adminis-
tration, leading to the exclusive use of tranexamic acid in 
these countries.
Th   is shift highlighted a number of problems concerning 
tranexamic acid. Th  e ﬁ  rst was to deﬁ  ne an appropriate 
eﬀ  ective dose. Th  ere is only one study investigating a 
dose-response relationship [3]. Th  is article showed a 
plateau eﬀ  ect on drains losses with a total dose of 3 grams 
tranexamic acid but with no observed eﬀ  ect on trans  fu-
sions. Th   e population studied were patients having low-
risk primary myocardial revascularisation. Th  e second 
problem is that there is no evidence for a beneﬁ  t  of 
tranexamic acid to reduce transfusion burden in patients 
at higher risk for transfusions, such as those taking 
aspirin prior to surgery [4] and those having prolonged 
bypass periods associated with more complex, typically 
combined valve and revascularisation surgery. Th  e 
current article [1] mirrors a meta-analysis showing re-
exploration for bleeding is reduced by aprotinin but not 
tranexamic acid in such patients [5]. Finally, and of 
crucial importance, there have never been any speciﬁ  cally 
powered studies to investigate the safety of tranexamic 
acid.
Over the past months a number of articles have 
suggested the use of tranexamic acid is not without risk. 
In an extension of a previous analysis from Toronto, the 
authors concluded that mortality after cardiac surgery 
other than primary revascularisation was greater in those 
patients given tranexamic acid compared to those given 
high dose aprotinin [6]. An increase in mortality when 
tranexamic acid was given instead of aprotinin is also a 
conclusion from the current article [1].
Neurological outcomes is a long standing safety 
concern as we know administration of tranexamic acid is 
associated with clinically signiﬁ  cant cerebral vasospasm 
with acute cerebral haemorrhage [7]. Th   e current article 
[1] shows a three-fold increase in patients having seizures 
who were allocated to receive high dose tranexamic acid 
as part of their management during surgery where a 
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© 2010 BioMed Central Ltdcardiac chamber was opened. Can this observation be 
causally associated with tranexamic acid administration?
Th  e statistical analysis used in the current study was 
similar to that used to show a deleterious eﬀ  ect  of 
aprotinin, which has subsequently been shown to be 
ﬂ  awed. However, an analysis error seems less likely in this 
case for two reasons. First, a potential mechanism for 
altering the excitatory neuronal state is recognised. Th  e 
lysine analogues have marked structural homology with 
gamma amino butyric acid (GABA) and act as 
competitive inhibitors in the central nervous system 
[8,9]. Th   is inhibition is observed clinically as an increase 
in seizure activity [9,10]. Second, several other groups 
have independently made the observation of increased 
seizure activity, mainly in patients having open cardiac 
chamber procedures [11,12].
What can and should happen next? Th  e European 
regulatory authority is currently deliberating on not only 
the licensing for aprotinin but also tranexamic acid [2]. 
With the increasing body of evidence, it is becoming 
clearer that aprotinin therapy is of greatest beneﬁ  t  in 
patients at highest risk (the originally intended patient 
population [13]). Th  e data also suggest that tranexamic 
acid in a dose of about 3 to 5 grams may be useful to 
reduce transfusion burden in patients not taking platelet 
active medication and having primary myocardial 
revascularisation. Th   is patient population appears not to 
have observed safety issues when tranexamic acid was 
administered [5]. Th  e current study adds to the data 
questioning if tranexamic acid administration has a place 
in higher risk cardiac surgery and especially in surgery 
where a cardiac chamber is opened.
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